News

Featured news from NHIVNA

HIV-related news from NAM

PrEP likely to be cost effective in middle-income countries, but its use will be too costly to make a big difference in HIV rate
Gus Cairns, 2012-10-12 09:40:00

What is probably the most detailed and realistic modelling study so far done of the impact and cost-effectiveness of pre-exposure prophylaxis (PrEP) finds that it could be very cost-effective in terms of the price of an extra year of healthy life for an individual taking it.

However its absolute cost is likely to restrict its use to only the highest-risk individuals in a population, and this may mean it may only make a minor impact on HIV incidence.

These, at least, will be the effects forecast amongst men who have sex with men (MSM) and transgender women (TGs) in the capital of a middle-income country. The country in the model is Lima, Peru, and the reason it was chosen as the base for the model is because it featured the highest number of enrolments to the seminal iPrEx study of PrEP in MSM/TGs, the first of several to report significant efficacy (in the case of iPrEx it cut HIV infections by 44%, even though only 50% of trial participants took enough doses of PrEP for it to work).

The inputs for the model were derived both from the data produced by iPrEx and from the anthropological and social research into the MSM/TG communities of Lima and Peru conducted in advance of the actual study, and which was crucial to its success because it enabled appropriate targeting and recruitment.

Source:1